Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial

The randomized, phase III ALFA-0701 trial showed that a reduced and fractionated dose of gemtuzumab ozogamicin added to standard front-line chemotherapy significantly improves event-free survival (EFS) in adults with de novo acute myeloid leukemia (AML). Here we report an independent review of EFS,...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Haematologica
Asıl Yazarlar: Lambert, Juliette, Pautas, Cécile, Terré, Christine, Raffoux, Emmanuel, Turlure, Pascal, Caillot, Denis, Legrand, Ollivier, Thomas, Xavier, Gardin, Claude, Gogat-Marchant, Karïn, Rubin, Stephen D., Benner, Rebecca J., Bousset, Pierre, Preudhomme, Claude, Chevret, Sylvie, Dombret, Herve, Castaigne, Sylvie
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Ferrata Storti Foundation 2019
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6312010/
https://ncbi.nlm.nih.gov/pubmed/30076173
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.188888
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller